Layoffs Coming In Oncology

Discussion in 'Eisai' started by anonymous, Sep 28, 2017 at 10:59 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


    I'm not THAT GUY - but your spelling comes across as a functional idiot.
     

  2. anonymous

    anonymous Guest

    coming from a guy looking for career advice on cafe pharma, who’s the idiot?
     
  3. anonymous

    anonymous Guest

    [They are hiring for Onoc expansion- expecting a new indication for Met. Liver etc for Onco. Is this secure or no... for midwest area. Also what do you mean company car no personal?? Can you opt out and take a car allowance? Interviewing this week-please serious replies Thank you
     
  4. anonymous

    anonymous Guest

    no car allowance, restrictions on use of the company car.
     
  5. anonymous

    anonymous Guest

    Can you elaborate on the restrictions of a company car? What does a typical week look like? Call logs vs actual sales calls ratio? Some one mentioned 2 hr conf calls? Are you tracked on your car or something? Is this new manager micro manager? How realistic is it to hit your sales goals? Thank you for any serious feed back
     
  6. anonymous

    anonymous Guest

     
  7. anonymous

    anonymous Guest

    cant drive car more than 250 miles from home and pay out of pocket for gas on pto.
     
  8. anonymous

    anonymous Guest

    and they still deduct personal use from your pay, it’s a joke.
     
  9. anonymous

    anonymous Guest

    Midwest area? Depends a lot on the manager. Stay away from Dill Goyle for sure! JW and KC are great!
     
  10. anonymous

    anonymous Guest

    Vic, give it up! Drama drama.
     
  11. anonymous

    anonymous Guest

    Eisai is in oncology?
     
  12. anonymous

    anonymous Guest

     
  13. anonymous

    anonymous Guest

    Eisai is the place to leave.
     
  14. anonymous

    anonymous Guest

    didnt merk just agree to pay Eisai 5.4 billion to co promote?

    Oh and AS did the dude...
     
  15. anonymous

    anonymous Guest

    and apparently Merck thinks Eisai is in Oncology too
     
  16. anonymous

    anonymous Guest

    While this is great news for Eisai and the cash is a bridge to our (mostly neurology) pipeline, we just sold off half of the rights to our most promising oncology product.
     
  17. anonymous

    anonymous Guest

    No. Actually read the contract. Merck is reimbursing Eisai about 460M for Lemvina research costs. There are milestone payments built in of about 5B IF Lemvina has record sales. Merck doesn’t have to pay most of that if Levima is a flop. Merck hedged their bet with an acquisition market in oncology. Unless the combo lung data is fantastic when it reads out I don’t expect much. HCC will not be a blockbuster launch like Eisai is planning. Look at the RCC failure.
     
  18. anonymous

    anonymous Guest

    Eisai is in oncology?